Archive - February 2019
Ipsen buys rare disease group Clementia in $1.3bn deal
Roche to pay $4.3bn for Spark in gene therapy move
Research finds PTSD affects 8% of under 18s
Cancer screening programmes to get an independent review
Boehringer Ingelheim signs drug discovery pact with 3B Pharmaceuticals
Prescriptions to rise to £9 from April
Novartis in-licenses Akcea’s novel cardiovascular therapy
Roche buys gene therapy specialist Spark for $4.3bn
